Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2012 December;37(4) > Minerva Endocrinologica 2012 December;37(4):329-34

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

  THYROIDOLOGY


Minerva Endocrinologica 2012 December;37(4):329-34

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Surgical management of medullary thyroid cancer

Mazeh H. 1, 2, Sippel R. S. 1

1 Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, Madison, WI, USA; 2 Section of Endocrine Surgery, Department of Surgery, Hadassah-Hebrew, University Medical Center, Mount Scopus Jerusalem, Israel


PDF  


Although thyroid cancer accounts for only 1.5% of all malignancies in the US it is the most rapidly increasing cancer in incidence and it is the most common endocrine malignancy that accounts for over 95% of the endocrine malignancies. Medullary thyroid cancer (MTC) originates from the parafollicular C cells and it represents 6-8% of all thyroid cancer cases. As many as 25% of the MTCs are familial and carry a specific germline mutation as compared to only than 10% familial inheritance in non-medullary thyroid cancers. While well-differentiated thyroid malignancies carry a very good prognosis, recurrence and survival rates of patients with MTC are significantly worse. The difference in cell origin and differentiation also results in different available adjunct therapy. The aim of this study is to review in detail the surgical management of patients with MTC.

top of page

Publication History

Cite this article as

Corresponding author e-mail

sippel@surgery.wisc.edu